Cancer Therapeutics Innovation Group, LLC – Trademark Portfolio
Entity Type: 16
Cancer Therapeutics Innovation Group, LLC holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 10 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 5 Nice Classification classes. The owner is based in New York, NY.
777 Third Avenue, Suite 14A
New York, NY 10017
Showing of trademarks Trademarks
Trademark Classifications
Cancer Therapeutics Innovation Group, LLC's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Insurance; financial affairs; monetary affairs; real estate affairs
Advertising; business management; business administration; office functions
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Cancer Therapeutics Innovation Group, LLC have?
Cancer Therapeutics Innovation Group, LLC has 15 U.S. trademarks filed with the USPTO.
What trademark classes does Cancer Therapeutics Innovation Group, LLC file in?
Cancer Therapeutics Innovation Group, LLC files trademarks across 5 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 36 (Insurance & Financial), Class 35 (Advertising & Business), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What is Cancer Therapeutics Innovation Group, LLC's trademark registration success rate?
Cancer Therapeutics Innovation Group, LLC has a 0% trademark registration rate, with 0 out of 15 resolved applications resulting in successful registration. Currently, 0 applications are pending review.